CN109097341A - 一种同时表达ha和hef的复制缺陷型重组流感病毒 - Google Patents
一种同时表达ha和hef的复制缺陷型重组流感病毒 Download PDFInfo
- Publication number
- CN109097341A CN109097341A CN201810983363.XA CN201810983363A CN109097341A CN 109097341 A CN109097341 A CN 109097341A CN 201810983363 A CN201810983363 A CN 201810983363A CN 109097341 A CN109097341 A CN 109097341A
- Authority
- CN
- China
- Prior art keywords
- influenza
- virus
- hef
- type
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 20
- 230000007547 defect Effects 0.000 title claims abstract description 8
- 230000010076 replication Effects 0.000 title claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 45
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 26
- 208000037797 influenza A Diseases 0.000 claims abstract description 13
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 108090000371 Esterases Proteins 0.000 claims abstract description 5
- 230000002238 attenuated effect Effects 0.000 claims abstract description 5
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 5
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 13
- 102000005348 Neuraminidase Human genes 0.000 claims description 8
- 108010006232 Neuraminidase Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 108091092724 Noncoding DNA Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 4
- 238000006062 fragmentation reaction Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 101150080862 NA gene Proteins 0.000 claims description 3
- 108700026244 Open Reading Frames Proteins 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010069767 H1N1 influenza Diseases 0.000 claims description 2
- 201000010740 swine influenza Diseases 0.000 claims description 2
- 241001500343 Influenzavirus C Species 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 5
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 5
- 101710154606 Hemagglutinin Proteins 0.000 abstract description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract description 4
- 101710176177 Protein A56 Proteins 0.000 abstract description 4
- 239000000185 hemagglutinin Substances 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 229940125575 vaccine candidate Drugs 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000016379 mucosal immune response Effects 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 230000000192 social effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 41
- 239000000243 solution Substances 0.000 description 32
- 239000007788 liquid Substances 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000002574 poison Substances 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 5
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012124 Opti-MEM Substances 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 101150076514 NS gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (8)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810983363.XA CN109097341B (zh) | 2018-08-28 | 2018-08-28 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
PCT/CN2018/114271 WO2020042359A1 (zh) | 2018-08-28 | 2018-11-07 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810983363.XA CN109097341B (zh) | 2018-08-28 | 2018-08-28 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109097341A true CN109097341A (zh) | 2018-12-28 |
CN109097341B CN109097341B (zh) | 2021-09-24 |
Family
ID=64851500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810983363.XA Expired - Fee Related CN109097341B (zh) | 2018-08-28 | 2018-08-28 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109097341B (zh) |
WO (1) | WO2020042359A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111481663A (zh) * | 2020-04-09 | 2020-08-04 | 广州医科大学 | 一种流感病毒活疫苗及其制备方法 |
CN115998854A (zh) * | 2023-01-30 | 2023-04-25 | 南京市第二医院 | 一组流感病毒基因的非编码区在制备mRNA疫苗中的应用 |
CN116144612A (zh) * | 2022-12-08 | 2023-05-23 | 广州医科大学附属第一医院(广州呼吸中心) | 重组乙型流感病毒及其制备方法与应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134138A1 (en) * | 1999-04-06 | 2006-06-22 | Yoshihiro Kawaoka | Recombinant influenza viruses for vaccines and gene therapy |
US20100029579A1 (en) * | 2007-01-23 | 2010-02-04 | Therapicon Srl | Antiviral compounds |
CN101796190A (zh) * | 2007-06-27 | 2010-08-04 | 阿维尔绿山生物技术研究发展贸易股份公司 | 用于表达异源序列的复制缺陷型流感病毒 |
CN101851636A (zh) * | 1999-04-06 | 2010-10-06 | 威斯康星校友研究基金会 | 用于疫苗和基因治疗的重组流感病毒 |
CN102112155A (zh) * | 2008-06-05 | 2011-06-29 | 埃博灵克斯股份有限公司 | 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽 |
US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
CN102939096A (zh) * | 2010-02-18 | 2013-02-20 | 西奈山医学院 | 用于预防和治疗流感病毒疾病的疫苗 |
US20130177587A1 (en) * | 2003-07-11 | 2013-07-11 | Novavax, Inc. | Functional influenza virus-like particles (vlps) |
CN103316357A (zh) * | 2013-02-05 | 2013-09-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法 |
CN103757032A (zh) * | 2014-01-28 | 2014-04-30 | 中国人民解放军第三0二医院 | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 |
CN105754961A (zh) * | 2016-03-30 | 2016-07-13 | 中国农业科学院哈尔滨兽医研究所 | 表达类禽型h1n1猪流感病毒ha蛋白的重组复制缺陷型腺病毒及其构建方法和用途 |
CN109136199A (zh) * | 2018-09-14 | 2019-01-04 | 青岛农业大学 | 一种表达h5亚型ha的复制缺陷型重组h9n2禽流感病毒 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183740A1 (en) * | 2010-06-02 | 2013-07-18 | Avir Green Hills Biotechnology Research Development Trade Ag | Novel method for generation of rna virus |
EP2747778B1 (en) * | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
WO2017087492A1 (en) * | 2015-11-16 | 2017-05-26 | Kansas State University Research Foundation | Influenza virus vaccine and vaccine platform |
-
2018
- 2018-08-28 CN CN201810983363.XA patent/CN109097341B/zh not_active Expired - Fee Related
- 2018-11-07 WO PCT/CN2018/114271 patent/WO2020042359A1/zh active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134138A1 (en) * | 1999-04-06 | 2006-06-22 | Yoshihiro Kawaoka | Recombinant influenza viruses for vaccines and gene therapy |
CN101851636A (zh) * | 1999-04-06 | 2010-10-06 | 威斯康星校友研究基金会 | 用于疫苗和基因治疗的重组流感病毒 |
US20130177587A1 (en) * | 2003-07-11 | 2013-07-11 | Novavax, Inc. | Functional influenza virus-like particles (vlps) |
US20100029579A1 (en) * | 2007-01-23 | 2010-02-04 | Therapicon Srl | Antiviral compounds |
CN101796190A (zh) * | 2007-06-27 | 2010-08-04 | 阿维尔绿山生物技术研究发展贸易股份公司 | 用于表达异源序列的复制缺陷型流感病毒 |
CN102112155A (zh) * | 2008-06-05 | 2011-06-29 | 埃博灵克斯股份有限公司 | 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽 |
US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
CN102939096A (zh) * | 2010-02-18 | 2013-02-20 | 西奈山医学院 | 用于预防和治疗流感病毒疾病的疫苗 |
CN103316357A (zh) * | 2013-02-05 | 2013-09-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法 |
CN103757032A (zh) * | 2014-01-28 | 2014-04-30 | 中国人民解放军第三0二医院 | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 |
CN105754961A (zh) * | 2016-03-30 | 2016-07-13 | 中国农业科学院哈尔滨兽医研究所 | 表达类禽型h1n1猪流感病毒ha蛋白的重组复制缺陷型腺病毒及其构建方法和用途 |
CN109136199A (zh) * | 2018-09-14 | 2019-01-04 | 青岛农业大学 | 一种表达h5亚型ha的复制缺陷型重组h9n2禽流感病毒 |
Non-Patent Citations (18)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111481663A (zh) * | 2020-04-09 | 2020-08-04 | 广州医科大学 | 一种流感病毒活疫苗及其制备方法 |
CN116144612A (zh) * | 2022-12-08 | 2023-05-23 | 广州医科大学附属第一医院(广州呼吸中心) | 重组乙型流感病毒及其制备方法与应用 |
CN116144612B (zh) * | 2022-12-08 | 2023-11-10 | 广州医科大学附属第一医院(广州呼吸中心) | 重组乙型流感病毒及其制备方法与应用 |
CN115998854A (zh) * | 2023-01-30 | 2023-04-25 | 南京市第二医院 | 一组流感病毒基因的非编码区在制备mRNA疫苗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109097341B (zh) | 2021-09-24 |
WO2020042359A1 (zh) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111560354B (zh) | 重组新型冠状病毒及其制备方法和应用 | |
JP4243349B2 (ja) | インフルエンザウイルスの複製のための動物細胞および方法 | |
Stucker et al. | The role of evolutionary intermediates in the host adaptation of canine parvovirus | |
CN109097341A (zh) | 一种同时表达ha和hef的复制缺陷型重组流感病毒 | |
CN109563492A (zh) | 突变的病毒、其制备方法和应用 | |
JP2006296437A (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
CN105331636A (zh) | 一种稳定表达猪瘟病毒e2蛋白的重组细胞系及其应用 | |
CN103751773B (zh) | 稳定表达猪瘟病毒e0-e1-e2蛋白的重组bhk细胞系及其在制备猪瘟疫苗与诊断试剂中的应用 | |
CN109136199A (zh) | 一种表达h5亚型ha的复制缺陷型重组h9n2禽流感病毒 | |
CN110272473A (zh) | 甲型流感通用型病毒样颗粒及其制备方法和应用 | |
Jazaeri Farsani et al. | Culturing of respiratory viruses in well‐differentiated pseudostratified human airway epithelium as a tool to detect unknown viruses | |
CN104611299B (zh) | 一种人工重组的h9n2禽流感病毒株、制备方法、疫苗组合物及其应用 | |
US11512117B1 (en) | Whole avian-origin reverse genetic system and recombinant H5N2 subtype avian influenza virus, vaccine and uses thereof | |
CN110205321A (zh) | 一种dna片段及其在构建表达红色荧光蛋白基因的重组流感病毒中的应用 | |
CN105121634B (zh) | 具有提高的病毒生产能力的细胞系及其生产方法 | |
CN110172452A (zh) | 一种高致病性h7n9禽流感病毒、疫苗、检测试剂以及病毒、疫苗的制备方法 | |
CN106755087A (zh) | 稳定表达猪瘟病毒e2蛋白的重组细胞系、制备方法、应用、及猪瘟病毒亚单位疫苗 | |
CN109182248A (zh) | 一种猪瘟病毒抗体检测elisa诊断试剂盒 | |
CN109136264A (zh) | 马疱疹病毒1型gB-gD融合蛋白、重组载体和真核细胞株及其制备方法和疫苗 | |
WO2012171329A1 (zh) | 一种核酸分离的方法及其应用 | |
CN109971888A (zh) | 一种复制可控型流感病毒的检测方法 | |
CN109180821A (zh) | 鸡新城疫病毒的融合蛋白及其制备方法、应用和疫苗 | |
CN108265079A (zh) | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 | |
Thangavel et al. | " Boom" and" Bust" cycles in virus growth suggest multiple selective forces in influenza a evolution | |
Szerman et al. | The small hydrophobic (SH) gene of North American turkey AMPV-C does not attenuate nor modify host tropism in recombinant European duck AMPV-C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Hongliang Inventor after: Li Junwei Inventor after: Li Guimei Inventor after: Song Xiaoming Inventor after: Liu Bo Inventor after: Shan Hu Inventor before: Li Junwei Inventor before: Sun Minghong Inventor before: Liu Bo Inventor before: Shan Hu |
|
CB03 | Change of inventor or designer information | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210924 |